Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil infusion rate during fetoscopic laser surgery for twin-to-twin transfusion syndrome
ACTRN12617000098336Phase 4Active, not recruiting
- Sponsor
- Department of anesthesiology, Shengjing hospital, China medical university
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remifentanil in twin-twin transfusion syndrome (TTTS) (3 arms), sponsored by Department of anesthesiology, Shengjing hospital, China medical university. Primary endpoints: Mean arterial pressure, Oxygen saturation and 1 more. Started Apr 2016; status: active, not recruiting.
02
Drugs
remifentanil
03
Conditions
twin-twin transfusion syndrome (TTTS)
Beyond the preview
Go deeper on ACTRN12617000098336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000098336.